Hookipa Pharma (NASDAQ:HOOK) Given New $48.00 Price Target at Royal Bank of Canada

Hookipa Pharma (NASDAQ:HOOK) had its target price cut by Royal Bank of Canada from $50.00 to $48.00 in a research note issued to investors on Friday morning, Marketbeat.com reports. They currently have an outperform rating on the stock.

Separately, JMP Securities boosted their price target on shares of Hookipa Pharma from $23.00 to $24.00 and gave the stock a “market outperform” rating in a report on Friday, August 9th.

Hookipa Pharma Trading Down 4.5 %

Shares of Hookipa Pharma stock opened at $3.00 on Friday. The business’s fifty day simple moving average is $4.09 and its 200 day simple moving average is $5.72. Hookipa Pharma has a 12 month low of $2.85 and a 12 month high of $11.30. The firm has a market capitalization of $36.18 million, a P/E ratio of -0.81 and a beta of 0.84.

Institutional Trading of Hookipa Pharma

Several hedge funds have recently made changes to their positions in HOOK. Acadian Asset Management LLC grew its stake in shares of Hookipa Pharma by 85.8% during the 1st quarter. Acadian Asset Management LLC now owns 882,262 shares of the company’s stock worth $627,000 after acquiring an additional 407,532 shares during the period. Renaissance Technologies LLC boosted its position in Hookipa Pharma by 38.4% during the second quarter. Renaissance Technologies LLC now owns 302,246 shares of the company’s stock worth $179,000 after purchasing an additional 83,800 shares during the period. Ikarian Capital LLC purchased a new position in shares of Hookipa Pharma in the third quarter worth about $228,000. Finally, Virtu Financial LLC bought a new stake in shares of Hookipa Pharma in the first quarter valued at approximately $31,000. 63.88% of the stock is currently owned by institutional investors.

About Hookipa Pharma

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.